Journal: Journal of Translational Medicine
Article Title: Cathepsin H as a causal risk factor and therapeutic target in proliferative diabetic retinopathy
doi: 10.1186/s12967-025-07314-4
Figure Lengend Snippet: Effects of PF429242 and SSR 69071 on HUVEC healing rate, and lysosomal function. ( A ) Representative images of HUVECs at 0, 12, and 24 hours after treatment with different concentrations of PF429242 (veh, 2.5, 5, 10 μM); ( B ) Healing rate of HUVECs at 0 and 12 hours after treatment with different concentrations of PF429242 (veh, 2.5, 5, 10 μM); ( C ) Healing rate of HUVECs at 0 and 24 hours after treatment with different concentrations of PF429242 (veh, 2.5, 5, 10 μM); ( D ) Representative images of HUVECs at 0, 12, and 24 hours after treatment with different concentrations of SSR 69071 (veh, 0.01, 0.1, 1 μM); ( E ) Healing rate of HUVECs at 0 and 12 hours after treatment with different concentrations of SSR 69071 (0, 0.01, 0.1, 1 μM); ( F ) Healing rate of HUVECs at 0 and 24 hours after treatment with different concentrations of SSR 69071 (0, 0.01, 0.1, 1 μM); ( G ) Representative images of HUVECs treated with 10 μM PF429242 or 1 μM SSR 69071 for 4 hours, detected by LysoTracker Red staining (nuclei counterstained with Hoechst 33,342). ( H ) Representative images of HUVECs treated with 10 μM PF429242 or 1 μM SSR 69071 for 4 hours, captured by a Multi-SIM system, with lysosomes stained by LysoTracker Red and nuclei counterstained with Hoechst 33342. ( I ) Lysosomal area per cell of HUVECs treated with 10 μM PF429242 or 1 μM SSR 69071 for 4 hours. * p < 0.05; ** p < 0.01; *** p < 0.001
Article Snippet: SSR 69071 and PF429242 (MedChemExpress, USA) were dissolved in 0.1% dimethyl sulfoxide (DMSO, MP Biomedicals, USA) and ultrapure water, respectively, to prepare stock solutions, then serially diluted with complete medium to working concentrations (SSR 69071, 0.001–10 μΜ/mL; PF429242 , 2.5–40 μM/mL) for 24-h treatment.
Techniques: Staining